OTHER INFORMATION
+Added: Departure of Directors or Certain Officers
+Added: Marc Tessier-Lavigne, our co-founder and a Board member, has recently informed us of his intention to step down from the Board effective September 1, 2025 to focus on his increased commitments as CEO and Chairman of Xaira Therapeutics, Inc.
+Added: The Board extends its gratitude to Marc for his significant contributions to Denali over the past decade.
+Added: We wish him and Xaira continued success.
Securities Trading Plans of Directors and Executive Officers
−Removed: No officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the first quarter ended March 31, 2025.
+Added: No officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the second quarter ended June 30, 2025.
EXHIBIT INDEX
2 unchanged sentences
Number Filing Date
−Removed: Notice of Partial Termination from Genzyme Corporation to the Registrant, dated February 24, 2025
−Removed: — — — Filed herewith
−Removed: Notice of Partial Termination from Takeda Pharmaceutical Company Limited to the Registrant, dated February 25, 2025
−Removed: — — — Filed herewith
−Removed: 10.3 Amended O utside D irector C ompensation P olicy
−Removed: — — — Filed herewith
+Added: 10.1 Executed Affiliate Registration Rights Agreement, dated June 3, 2025
+Added: 10.1 6/3/2025
31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.
17 unchanged sentences
— — — Furnished herewith
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2025, formatted in Inline XBRL (contained in Exhibit 101)
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2025, formatted in Inline XBRL (contained in Exhibit 101)
— — — Furnished herewith
4 unchanged sentences
DENALI THERAPEUTICS INC.
−Removed: May 6, 2025 By:
+Added: August 11, 2025 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: May 6, 2025 By:
+Added: August 11, 2025 By:
/s/ Alexander O.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.